Teva Expects Launches To Hold North American Generics Sales At $4bn Per Year

 
• By Aidan Fry

With a roster of launches planned over coming months, Teva is confident it can keep returning sales by its North American Generics operation in the region of $1bn per quarter.

Captain-steering-boat
A relatively stable trading environment and a healthy pipeline of launches should help Teva maintain its North American Generics sales at around $1bn per quarter, the firm believes • Source: Shutterstock

More from Generics

More from Products